Innoviva, Inc. (NasdaqGS: INVA)
Health Care · Pharmaceuticals · US
$21.21
+1.63% today · +21.5% 1Y
Innoviva, Inc. (NasdaqGS: INVA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.53B and employs 159 people.
Over the last twelve months the share price has gained 21.5%, trading between 16.52 and 25.15.
Tweenvest scores Innoviva, Inc. across four factors: quality 77/100, value 55/100, growth 36/100. Its strongest factor is quality.
INVA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.53B
- Revenue (TTM)
- $440.00M
- P/E
- 4.92
- EPS
- 4.31
- Dividend yield
- —
- Beta (5Y)
- 0.38
- 52-week high
- $25.15
- 52-week low
- $16.52
- Avg volume (3M)
- —
- Shares outstanding
- 72.25M
- Employees
- 159
- Next earnings
- —
About Innoviva, Inc.
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
- ISIN
- US45781M1018
- Founded
- 1996
- Listed since
- Oct 5, 2004
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.SZSE: 300357 | $1.56B | CN¥19.99 | -1.67% |
| Square Pharmaceuticals PLC.DSE: SQURPHARMA | $1.56B | Tk217.10 | -0.55% |
| Phibro Animal Health CorporationNasdaqGM: PAHC | $1.56B | $38.30 | +2.41% |
| North China Pharmaceutical Company.LtdSHSE: 600812 | $1.54B | CN¥6.03 | +21.08% |
| Jubilant Pharmova LimitedBSE: 530019 | $1.52B | Rs931.20 | -6.94% |
| Lotus Pharmaceutical Co., Ltd.TWSE: 1795 | $1.52B | NT$180.50 | +2.56% |
| Caregen Co., Ltd.KOSDAQ: A214370 | $1.52B | ₩41,800.00 | -1.76% |
| AstraZeneca Pharma India LimitedBSE: 506820 | $1.51B | Rs5,831.85 | -3.29% |
Figures last refreshed Oct 11, 2026.